OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

1 Projects | 1 Researchers | $2,225,237 Invested

2020

C2N Diagnostics

Kevin Yarasheski, PhD

Clinical Validation and Accreditation for Plasma Aß42/Aß40 as a Biomarker for Alzheimer’s Disease Pathology

  • Funding Amount: $2,225,237
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: zzAbeta
  • Status: Active